810222C
C6-NBD Glucosyl Ceramide
Manufacturer: Sigma Aldrich
CAS Number: 94885-03-7
Synonym(S): N-[6-[(7-nitro-2-1,3-benzoxadiazol-4-yl)amino]hexanoyl]-D-glucosyl-β1-1′-sphingosine
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| 250 μG | 810222C-250-μG | In Stock | ₹ 1,47,798.45 |
| 810222C-1MG | 810222C-810222C-1MG | In Stock | ₹ 1,89,607.50 |
810222C - 250 μG
In Stock
Quantity
1
Base Price: ₹ 1,47,798.45
GST (18%): ₹ 26,603.721
Total Price: ₹ 1,74,402.171
Assay
>99% (TLC)
form
liquid
packaging
pkg of 1 × 1 mL (810222C-250ug)pkg of 1 × 1 mg (81022C-1MG)
manufacturer/tradename
Avanti Polar Lipids 810222C
concentration
0.25 mg/mL (810222C-250ug)
shipped in
dry ice
storage temp.
−20°C
Other Options
| Image | Product Name | Manufacturer | Price Range | |
|---|---|---|---|---|
 | C6-NBD Glucosyl Ceramide | Sigma Aldrich | ₹ 97,880.40 - ₹ 1,62,266.75 | |
 | C6 NBD Glucosylceramide | ChemScene | ₹ 25,668.00 - ₹ 64,170.00 | |
 | 94885-03-7 | N-[(1S,2R,3E)-1-[(β-D-glucopyranosyloxy)methyl]-2-hydroxy-3-heptadecen-1-yl]-6-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]-hexanamide | A2B Chem | ₹ 37,475.28 |
Related Products
Description
- General description: C6-NBD Glucosyl Ceramide is a fluorescent derivative of biologically active compound, glucosyl ceramide.[1] Glucosyl ceramide belongs to the class of sphingolipids that are synthesized in the cis/medial-Golgi apparatus by the glycosylation of ceramide.[2]
- Application: C6-NBD Glucosyl Ceramide may be used as a substrate for glucocerebrosidase (GCase) activity assay in Drosophila melanogaster and mice.[3][4]
- Biochem/physiol Actions: Glucosylceramide is the precursor of different glycosphingolipids including gangliosides and sulfatides.[2] Glucosyl ceramide is also known to be responsible for axon growth of neural cells.[5] The accumulation of glucosyl ceramide is associated with an inherited lysosomal storage disorder, Gaucher′s disease.[6]
- Packaging: 5 mL Amber Glass Screw Cap Vial (81022C-1MG)
SAFETY INFORMATION
Pictograms
Signal Word
Danger
Hazard Statements
Precautionary Statements
P201 - P260 - P264 - P280 - P304 + P340 + P311 - P403 + P233
Hazard Classifications
Acute Tox. 3 Inhalation - Acute Tox. 4 Oral - Carc. 2 - Eye Irrit. 2 - Repr. 2 - Skin Irrit. 2 - STOT RE 1 - STOT SE 3
Target Organs
Central nervous system
WGK
WGK 3
Compare Similar Items
Show Difference
Assay: >99% (TLC)
form: liquid
packaging: pkg of 1 × 1 mL (810222C-250ug)pkg of 1 × 1 mg (81022C-1MG)
manufacturer/tradename: Avanti Polar Lipids 810222C
concentration: 0.25 mg/mL (810222C-250ug)
shipped in: dry ice
storage temp.: −20°C
Assay:
>99% (TLC)
form:
liquid
packaging:
pkg of 1 × 1 mL (810222C-250ug)pkg of 1 × 1 mg (81022C-1MG)
manufacturer/tradename:
Avanti Polar Lipids 810222C
concentration:
0.25 mg/mL (810222C-250ug)
shipped in:
dry ice
storage temp.:
−20°C
Assay: >99% (TLC)
form: powder
packaging: pkg of 1 × 1 mg (810222P-1MG)pkg of 1 × 250 μg (810222P-250ug)
manufacturer/tradename: Avanti Polar Lipids 810222P
concentration: __
shipped in: dry ice
storage temp.: −20°C
Assay:
>99% (TLC)
form:
powder
packaging:
pkg of 1 × 1 mg (810222P-1MG)pkg of 1 × 250 μg (810222P-250ug)
manufacturer/tradename:
Avanti Polar Lipids 810222P
concentration:
__
shipped in:
dry ice
storage temp.:
−20°C
Assay: >99% (TLC)
form: powder
packaging: pkg of 1 × 1 mg (810223P-1MG)pkg of 1 × 250 μg (810223P-250ug)
manufacturer/tradename: Avanti Polar Lipids
concentration: __
shipped in: dry ice
storage temp.: −20°C
Assay:
>99% (TLC)
form:
powder
packaging:
pkg of 1 × 1 mg (810223P-1MG)pkg of 1 × 250 μg (810223P-250ug)
manufacturer/tradename:
Avanti Polar Lipids
concentration:
__
shipped in:
dry ice
storage temp.:
−20°C
Assay: >99% (TLC)
form: powder
packaging: pkg of 1 × 50 μg (810227P-50ug)
manufacturer/tradename: Avanti Polar Lipids 810227P
concentration: __
shipped in: dry ice
storage temp.: −20°C
Assay:
>99% (TLC)
form:
powder
packaging:
pkg of 1 × 50 μg (810227P-50ug)
manufacturer/tradename:
Avanti Polar Lipids 810227P
concentration:
__
shipped in:
dry ice
storage temp.:
−20°C